{{Rsnum
|rsid=2069391
|Gene=CDK2
|Chromosome=12
|position=55966094
|Orientation=plus
|GMAF=0.03994
|Gene_s=CDK2,PMEL
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 82.3 | 17.7 | 0.0
| HCB | 100.0 | 0.0 | 0.0
| JPT | 100.0 | 0.0 | 0.0
| YRI | 87.1 | 12.9 | 0.0
| ASW | 86.0 | 12.3 | 1.8
| CHB | 100.0 | 0.0 | 0.0
| CHD | 96.3 | 3.7 | 0.0
| GIH | 90.1 | 9.9 | 0.0
| LWK | 91.8 | 8.2 | 0.0
| MEX | 96.6 | 3.4 | 0.0
| MKK | 87.8 | 12.2 | 0.0
| TSI | 91.2 | 8.8 | 0.0
| HapMapRevision=28
}}{{PMID Auto
|PMID=19258477
|Title=Candidate gene analysis using imputed genotypes: cell cycle single-nucleotide polymorphisms and ovarian cancer risk.
|OA=1
}}

{{PMID Auto
|PMID=18778477
|Title=Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival.
|OA=1
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}